Low back pain (LBP), a major musculoskeletal disorder, has been implicated as the number one cause of years lived with disability (YLDs) by the GBD survey (the Global Burden of Disease, Injuries, and Risk Factors Study). Although there are several contributing factors to LBP, the majority of cases involve degeneration of the intervertebral disc (IVD), followed by disc prolapse. If left untreated, progressive deterioration of the disc can lead to complications such as sciatica and spinal stenosis. Usually, such conditions are treated by surgical interventions, namely, discectomy, which involves the removal of the ruptured spinal disc, thereby decompressing the nerves and relieving pain symptoms. However, long-term clinical studies suggest the possibility of reherniation events, requiring revision surgeries. Although a lot of research has been ongoing in this field to look for effective non-surgical therapies to treat IVD, current therapies are restricted only to temporarily relieve pain without reversing the structural defects of the degenerated disc. Hence, the present research seeks to fill this gap by designing a photocrosslinkable injectable hydrogel system inspired by the proteoglycan-rich extracellular matrix of IVD that can be administered following discectomy to replace the lost nucleus pulposus tissue. Compared to current prostheses, this minimally invasive method may offer unique benefits for the non-surgical repair and restoration of degenerated and herniated IVDs. In light of this, my thesis will focus on the synthesis and fabrication of a photocrosslinkable HA-based hydrogel system with tunable chondroitin sulfate (CS) content, one of the primary ECM components of the native disc. Further, the present study will decipher the role of increasing CS content in modulating the degenerated disc microenvironment to prevent future reherniation events.